sunitinib + everolimus + chemotherapies recommended in france
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
Conditions
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
Trial Timeline
May 12, 2015 → Nov 18, 2019
NCT ID
NCT02264665About sunitinib + everolimus + chemotherapies recommended in france
sunitinib + everolimus + chemotherapies recommended in france is a pre-clinical stage product being developed by Novartis for Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive. The current trial status is completed. This product is registered under clinical trial identifier NCT02264665. Target conditions include Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02264665 | Pre-clinical | Completed |
Competing Products
20 competing products in Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive